A Drug‐Drug Interaction Study to Evaluate the Effect of TAS‐303 on CYP3A Activity in the Small Intestine and Liver

TAS‐303 (4‐piperidinyl 2,2‐diphenyl‐2‐[propoxy‐1,1,2,2,3,3,3‐d7] acetate hydrochloride) is a novel selective noradrenaline reuptake inhibitor being developed for the treatment of stress urinary incontinence. An in vitro study and a physiologically based pharmacokinetic model simulation showed that T...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical pharmacology 2020-06, Vol.60 (6), p.702-710
Hauptverfasser:	Kumagai, Yuji, Fujita, Tomoe, Maeda, Mika, Sasaki, Yoshinobu, Nagaoka, Makoto, Huang, Jinhong, Takenaka, Toru, Kawai, Masaki
Format:	Artikel
Sprache:	eng
Schlagworte:	Acetic acid clinical pharmacology clinical trials (CTRs) Cytochrome P450 Drug interaction Drug Interactions drug‐drug interactions Intravenous administration Midazolam model & simulation Norepinephrine Oral administration PBPK pharmaceutical R & D (PRD) Pharmacokinetics Simvastatin Small intestine Urinary incontinence
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!